MEDP in the 13F filings
Medpace HLDGS Inc · CUSIP 58506Q109
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 23 Jan 2026
- Managers listing it
- 34
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 16 listed it in both
- Shares listed
- 4,967,987
- combined, among listed positions
- Reported value
- $2.8bn
- combined, at the quarter end
Among the 92 comparable managers: 14 buyers (opened or added shares) and 21 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +329,035.
Managers listing MEDP in Q4 2025
34 of 34 holders
Largest increases and reductions, by shares
Increases
- AQR Capital Management LLCexisting position · 1,349,703 shares now+324,293
- Fidelity (FMR LLC)existing position · 203,721 shares now+195,907
- Tudor Investment Corpexisting position · 89,242 shares now+66,232
- Arrowstreet Capital LPexisting position · 375,033 shares now+60,883
- Marshall Wace LLPexisting position · 44,951 shares now+38,359
Reductions
- D. E. Shaw & Co.existing position · 528,232 shares now-71,908
- Millennium Management LLCexisting position · 51,991 shares now-64,620
- Invesco Ltdexisting position · 482,625 shares now-54,782
- Voloridge Investment Management LLCexisting position · 139,361 shares now-51,633
- Two Sigma Advisers LPexisting position · 40,960 shares now-47,240
New positions and exits
New (2)
Exited (2)
- Freestone Grove Partners LPwas $10m
- Schonfeld Strategic Advisors LLCwas $4.6m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 2 | $21m | n.a. | n.a. |
| Q2 2017 | 1 | $14m | n.a. | n.a. |
| Q3 2017 | 1 | $19m | n.a. | n.a. |
| Q4 2017 | 1 | $23m | n.a. | n.a. |
| Q1 2018 | 3 | $37m | n.a. | n.a. |
| Q2 2018 | 4 | $59m | n.a. | n.a. |
| Q3 2018 | 14 | $247m | n.a. | n.a. |
| Q4 2018 | 6 | $119m | n.a. | n.a. |
| Q1 2019 | 4 | $100m | n.a. | n.a. |
| Q2 2019 | 4 | $117m | n.a. | n.a. |
| Q3 2019 | 6 | $140m | n.a. | n.a. |
| Q4 2019 | 5 | $122m | n.a. | n.a. |
| Q1 2020 | 7 | $144m | n.a. | n.a. |
| Q2 2020 | 8 | $173m | n.a. | n.a. |
| Q3 2020 | 12 | $218m | n.a. | n.a. |
| Q4 2020 | 8 | $187m | n.a. | n.a. |
| Q1 2021 | 9 | $153m | n.a. | n.a. |
| Q2 2021 | 8 | $156m | n.a. | n.a. |
| Q3 2021 | 11 | $413m | n.a. | n.a. |
| Q4 2021 | 12 | $668m | n.a. | n.a. |
| Q1 2022 | 6 | $107m | n.a. | n.a. |
| Q2 2022 | 5 | $97m | n.a. | n.a. |
| Q3 2022 | 3 | $59m | n.a. | n.a. |
| Q4 2022 | 10 | $269m | n.a. | n.a. |
| Q1 2023 | 14 | $275m | n.a. | n.a. |
| Q2 2023 | 17 | $468m | n.a. | n.a. |
| Q3 2023 | 15 | $378m | n.a. | n.a. |
| Q4 2023 | 14 | $501m | 8 | 7 |
| Q1 2024 | 17 | $1.2bn | 9 | 8 |
| Q2 2024 | 18 | $1.3bn | 9 | 9 |
| Q3 2024 | 15 | $918m | 9 | 6 |
| Q4 2024 | 15 | $1.2bn | 9 | 6 |
| Q1 2025 | 12 | $986m | 11 | 1 |
| Q2 2025 | 14 | $1.2bn | 12 | 3 |
| Q3 2025 | 17 | $1.9bn | 9 | 8 |
| Q4 2025 | 14 | $2.1bn | 14 | 21 |
| Q1 2026 | 12 | $1.8bn | 12 | 21 |
| Q2 2026 | 9 | $2.7bn | 8 | 21 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MEDP and LLY →MEDP and JNJ →MEDP and VRTX →Choose a stock to compare with MEDP →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MEDP, latest filings →Back to the 13F Explorer →